Background: Mature thymocytes exhibit higher levels of CD28 than the immature cells. Activation of T cells results in enhanced CD28 expression. T cell activation requires two combined signals provided by antigen presenting cells. The first is mediated via the T cell receptor following its interaction with antigenic peptide MHC complexes, and the second is delivered by accessory or costimulating molecules through their counter receptors on T lymphocytes. CD28 bears structural homology to CTLA 4 which is expressed at very low levels on the surface of CD4+ and CD8+ peripheral blood cells only following activation. CD28 is the natural receptor for the B7/BB 1 ligand (CD80) a 55-60 kDa glycoprotein which is expressed on activated B lymphocytes, on dendritic cells and on interferon gamma treated monocytes. The binding of B7 1/BB 1 molecules to CD28 is involved in T lymphocyte activation and in the initiation and maintenance of chronic inflammation.
Description: Rabbit polyclonal to CD28
Immunogen: KLH conjugated synthetic peptide derived from CD28
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 25 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
